Malaria vaccine - Mymetics

Drug Profile

Malaria vaccine - Mymetics

Alternative Names: PEV 1002A; PEV 301; PEV 302; PEV3; PEV3A

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pevion Biotech
  • Developer Mymetics Corporation; Swiss Tropical Institute
  • Class Antimalarials; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Malaria

Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Malaria in Switzerland (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Malaria(In adolescents, In children) in Tanzania (Parenteral, Injection)
  • 05 Apr 2016 Data from a preclinical trial in Maleria released by Mymetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top